Gilead Sciences To Release Fourth Quarter & Full Year 2022 Financial Results On Thursday, February 2, 2023

On January 19, 2023 Gilead Sciences, Inc. (Nasdaq: GILD) reported that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes (Press release, Gilead Sciences, JAN 19, 2023, View Source;Full-Year-2022-Financial-Results-on-Thursday-February-2-2023/default.aspx [SID1234626399]). At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived there for one year.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!